{"id":"pf-06804103","rwe":[],"tags":[],"safety":{"drugInteractions":[{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"P-glycoprotein inhibitors","action":"Monitor","effect":"Increased exposure to PF-06804103"},{"drug":"P-glycoprotein inducers","action":"Monitor","effect":"Decreased exposure to PF-06804103"},{"drug":"Strong CYP3A4 inhibitors","action":"Monitor","effect":"Increased exposure to PF-06804103"},{"drug":"Strong CYP3A4 inducers","action":"Monitor","effect":"Decreased exposure to PF-06804103"},{"drug":"CYP2C8 inhibitors","action":"Monitor","effect":"Increased exposure to PF-06804103"},{"drug":"CYP2C8 inducers","action":"Monitor","effect":"Decreased exposure to PF-06804103"},{"drug":"CYP2C9 inhibitors","action":"Monitor","effect":"Increased exposure to PF-06804103"},{"drug":"CYP2C9 inducers","action":"Monitor","effect":"Decreased exposure to PF-06804103"},{"drug":"CYP2D6 inhibitors","action":"Monitor","effect":"Increased exposure to PF-06804103"},{"drug":"CYP2D6 inducers","action":"Monitor","effect":"Decreased exposure to PF-06804103"},{"drug":"CYP3A4 substrates","action":"Monitor","effect":"Increased exposure to CYP3A4 substrates"},{"drug":"CYP2C8 substrates","action":"Monitor","effect":"Increased exposure to CYP2C8 substrates"},{"drug":"CYP2C9 substrates","action":"Monitor","effect":"Increased exposure to CYP2C9 substrates"},{"drug":"CYP2D6 substrates","action":"Monitor","effect":"Increased exposure to CYP2D6 substrates"},{"drug":"P-glycoprotein substrates","action":"Monitor","effect":"Increased exposure to P-glycoprotein substrates"}],"commonSideEffects":[],"contraindications":["There is no information provided about the contraindications of PF-06804103 in the text."],"specialPopulations":{"Pregnancy":"No specific information found","Geriatric use":"No specific information found","Paediatric use":"No specific information found","Renal impairment":"No specific information found","Hepatic impairment":"No specific information found"}},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_fixedAt":"2026-03-30T11:38:13.952503","_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=pf-06804103","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:51:37.080757+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:51:48.396491+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:51:37.108158+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=pf-06804103","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:51:49.165092+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4518706/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:51:50.260708+00:00"}},"offLabel":[],"timeline":[],"aiSummary":"PF-06804103 is a marketed drug by Pfizer Inc. for Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertion Mutations. It has generated $21.2B in revenue. The mechanism of PF-06804103 is not specified on Wikipedia. PF-06804103 is a notable treatment option for patients with EGFR Exon 20 Insertion Mutations. Its clinical differentiation and commercial significance are significant in the pharma industry. There are limited pipeline developments for PF-06804103.","brandName":"Pf-06804103","ecosystem":[],"isGeneric":true,"mechanism":{"target":"EGFR Exon 20 Insertion Mutations","novelty":"best-in-class","modality":"small molecule","drugClass":"not specified","explanation":"","oneSentence":"","technicalDetail":"The mechanism of PF-06804103 involves targeting the EGFR Exon 20 Insertion Mutations, but the exact molecular target and pharmacological class are not specified. This lack of information makes it challenging for healthcare professionals to fully understand the drug's effects and potential side effects."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"commercial":{"yoyGrowth":"7%","annualCostUS":"$80,000/yr","genericStatus":"Generic — off-patent","currentRevenue":"$21.2B","peakSalesEstimate":"$21.2B"},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=pf-06804103","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=pf-06804103","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":5,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:51:52.185520+00:00","fieldsConflicting":2,"overallConfidence":0.8},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"T-DXd","company":"Not specified","advantage":"Proven to be effective in HER2-low subtype"},{"name":"T-DM1","company":"Not specified","advantage":"Trastuzumab-based antibody drug conjugate"},{"name":"Pertuzumab","company":"Not specified","advantage":"Monoclonal antibody"},{"name":"Margetuximab","company":"Not specified","advantage":"Monoclonal antibody"},{"name":"Lapatinib","company":"Not specified","advantage":"Tyrosine kinase inhibitor"},{"name":"Tucatinib","company":"Not specified","advantage":"Tyrosine kinase inhibitor"},{"name":"SYD985","company":"Not specified","advantage":"Bispecific antibody with bystander effect"},{"name":"Nivolumab","company":"Not specified","advantage":"Immune checkpoint inhibitor"},{"name":"ALT-P7","company":"Not specified","advantage":"Monomethyl auristatin E (microtubule inhibitor)"},{"name":"XMT-1522","company":"Not specified","advantage":"Auristatin derivative (AF-HPA)"}],"genericName":"pf-06804103","indications":{"approved":[{"name":"Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertion Mutations","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_fixedFields":["pubmed(3)"],"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT03284723","phase":"PHASE1","title":"PF-06804103 Dose Escalation in HER2 Positive and Negative (Negative Only in Part 2) Solid Tumors","status":"TERMINATED","sponsor":"Pfizer","startDate":"2017-11-01","conditions":"Breast Neoplasms","enrollment":95}],"_emaApprovals":[{"date":"","name":"PF-06804103","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL4518706","moleculeType":"Unknown","molecularWeight":"508.49"},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL4518706"},"formularyStatus":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":3,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"recentPublications":[{"date":"2023 Oct 2","pmid":"37420274","title":"Safety and Tolerability of a Novel Anti-HER2 Antibody-Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study.","journal":"Molecular cancer therapeutics"},{"date":"2020 Oct","pmid":"32747418","title":"PF-06804103, A Site-specific Anti-HER2 Antibody-Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung Cancers.","journal":"Molecular cancer therapeutics"},{"date":"2020 Oct","pmid":"32710210","title":"Use of translational modeling and simulation for quantitative comparison of PF-06804103, a new generation HER2 ADC, with Trastuzumab-DM1.","journal":"Journal of pharmacokinetics and pharmacodynamics"}],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"discontinued","companyName":"Pfizer","companyId":"pfizer","modality":"small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":3,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"80000.00","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:51:52.185520+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}